2019 Press Releases

»2019 Press Releases
15 04, 2019

Eiger BioPharmaceuticals Appoints Market Access, Public Policy Expert, and Biotech Veteran Amit K. Sachdev to Board of Directors

2019-04-15T12:26:41+00:00

Eiger BioPharmaceuticals Appoints Market Access, Public Policy Expert, and Biotech Veteran Amit K. Sachdev to Board of Directors PALO ALTO, Calif., April 15, 2019 -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of therapies for serious rare and ultra-rare diseases, announced today the appointment of Amit K. Sachdev, JD to its Board [...]

Eiger BioPharmaceuticals Appoints Market Access, Public Policy Expert, and Biotech Veteran Amit K. Sachdev to Board of Directors2019-04-15T12:26:41+00:00
11 04, 2019

Eiger Announces 36% Durable Virologic Response at 24 Weeks Post-Treatment with Peginterferon Lambda in Phase 2 LIMT HDV Study at The International Liver Congress™ 2019

2019-04-11T21:56:39+00:00

Eiger Announces 36% Durable Virologic Response at 24 Weeks Post-Treatment with Peginterferon Lambda in Phase 2 LIMT HDV Study at The International Liver Congress™ 2019 Improved Tolerability in HDV-infected Patients vs Historical Peginterferon Alfa Post-treatment Endpoint Results to be Discussed with Regulatory Agencies PALO ALTO, Calif., April 11, 2019 -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused [...]

Eiger Announces 36% Durable Virologic Response at 24 Weeks Post-Treatment with Peginterferon Lambda in Phase 2 LIMT HDV Study at The International Liver Congress™ 20192019-04-11T21:56:39+00:00
26 03, 2019

Eiger BioPharmaceuticals to Participate in Conferences in April

2019-03-26T13:24:24+00:00

Eiger BioPharmaceuticals to Participate in Conferences in April PALO ALTO, Calif. – March 26, 2019 – Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that management will present at upcoming investor, scientific, and orphan drug conferences in April. C. Wainwright Global [...]

Eiger BioPharmaceuticals to Participate in Conferences in April2019-03-26T13:24:24+00:00
25 03, 2019

Eiger BioPharmaceuticals Announces Oral Presentation of Phase 2 PREVENT Study Results of Avexitide in Post-Bariatric Hypoglycemia at Endocrine Society Meeting (ENDO) 2019

2019-03-25T17:57:47+00:00

Eiger BioPharmaceuticals Announces Oral Presentation of Phase 2 PREVENT Study Results of Avexitide in Post-Bariatric Hypoglycemia at Endocrine Society Meeting (ENDO) 2019 Statistically Significant Reduction in Hyperinsulinemic Hypoglycemia Reduced Rates of Hypoglycemia and Rescue in Outpatient Setting PALO ALTO, Calif., March 25, 2019 — Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization [...]

Eiger BioPharmaceuticals Announces Oral Presentation of Phase 2 PREVENT Study Results of Avexitide in Post-Bariatric Hypoglycemia at Endocrine Society Meeting (ENDO) 20192019-03-25T17:57:47+00:00
20 03, 2019

Eiger BioPharmaceuticals Management Team to Present and Participate in China Healthcare Investment Conference 2019

2019-03-20T13:29:54+00:00

Eiger BioPharmaceuticals Management Team to Present and Participate in China Healthcare Investment Conference 2019 PALO ALTO, Calif., March 20, 2019 – Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that David Cory, President and CEO, will present a corporate update at the [...]

Eiger BioPharmaceuticals Management Team to Present and Participate in China Healthcare Investment Conference 20192019-03-20T13:29:54+00:00
14 03, 2019

Eiger BioPharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Business Update

2019-03-14T22:50:48+00:00

Eiger BioPharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Business Update Began 2019 with $100.4 million in cash, cash equivalents & short-term investmentsEnrollment of Phase 3 D-LIVR Study in HDV planned by end of 2019NDA and MAA filings for Progeria and Progeroid Laminopathies planned in 2019 PALO ALTO, Calif., March 14, 2019 [...]

Eiger BioPharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Business Update2019-03-14T22:50:48+00:00
13 03, 2019

Eiger Late-Breaker Oral Presentation of Peginterferon Lambda Phase 2 LIMT Study at The International Liver Congress™ 2019

2019-03-13T14:34:05+00:00

Eiger Late-Breaker Oral Presentation of Peginterferon Lambda Phase 2 LIMT Study at The International Liver Congress™ 2019 36% Durable Virologic Response at 24 Weeks Post-Treatment PALO ALTO, Calif., March 13, 2019 -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced a late-breaker [...]

Eiger Late-Breaker Oral Presentation of Peginterferon Lambda Phase 2 LIMT Study at The International Liver Congress™ 20192019-03-13T14:34:05+00:00
11 03, 2019

Eiger BioPharmaceuticals Management Team to Present and Participate in Jefferies HBV Investor Summit

2019-03-11T15:07:06+00:00

Eiger BioPharmaceuticals Management Team to Present and Participate in Jefferies HBV Investor Summit PALO ALTO, Calif., March 11, 2019 – Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that David Cory, President and CEO, will present a corporate update at the Jefferies [...]

Eiger BioPharmaceuticals Management Team to Present and Participate in Jefferies HBV Investor Summit2019-03-11T15:07:06+00:00
4 03, 2019

Clinigen and Eiger BioPharmaceuticals launch worldwide Managed Access Program for lonafarnib for patients with Progeria and Progeroid Laminopathies

2019-03-04T15:41:48+00:00

Clinigen and Eiger BioPharmaceuticals launch worldwide Managed Access Program for lonafarnib for patients with Progeria and Progeroid Laminopathies Clinigen Group plc (AIM: CLIN, ‘Clinigen’), the global pharmaceutical and services company, has partnered with Eiger BioPharmaceuticals, Inc. (NASDAQ: EIGR, ‘Eiger’) to launch a worldwide lonafarnib Managed Access Program for patients with Progeria and Progeroid Laminopathies.Progeria, also [...]

Clinigen and Eiger BioPharmaceuticals launch worldwide Managed Access Program for lonafarnib for patients with Progeria and Progeroid Laminopathies2019-03-04T15:41:48+00:00
27 02, 2019

Eiger BioPharmaceuticals Announces the Appointment of Stephana Patton as General Counsel, Corporate Secretary, and Chief Compliance Officer

2019-02-27T14:57:39+00:00

Eiger BioPharmaceuticals Announces the Appointment of Stephana Patton as General Counsel, Corporate Secretary, and Chief Compliance Officer PALO ALTO, Calif., February 27, 2019 — Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced the appointment of Dr. Stephana Patton as the Company’s General [...]

Eiger BioPharmaceuticals Announces the Appointment of Stephana Patton as General Counsel, Corporate Secretary, and Chief Compliance Officer2019-02-27T14:57:39+00:00